RDLA December 2019 Newsletter

Reminder: Informational Webinar on Rare Disease Week will take place on December 12, 2019. The webinar will cover an overview of the events, travel stipends, and the Legislative Conference and include time for questions. Register to join on the RDLA website.

Capitol Hill Updates

FDA Commissioner Nomination: Dr. Stephen Hahn was formally nominated by the Trump administration to serve as the Food and Drug Administration (FDA) Commissioner on November 5, 2019. The Senate Health, Education, Labor, and Pensions (HELP) Committee voted 18 to 5 to approve Hahn’s nomination on December 3, 2019. Next the Senate will vote on Hahn’s nomination. Dr. Scott Gottlieb, the former FDA Commissioner, stepped down in April of 2019. Currently, Dr. Brett Giroir, a Department of Health and Human Services official, is acting as FDA Commissioner.

The MEDS Act: The Mitigating Emergency Drug Shortages. S. 2723, was introduced by Senators Susan Collins (ME) and Tina Smith (MN) on October 29, 2019. S. 2723 proposes to increase FDA’s authority, enhance manufacturing reporting requirements, and incentives to help reduce drug shortages and the risks shortages pose to patients.

The STAR Act: The Specialty Treatment to Access and Referrals Act, H.R. 5190, was introduced by Representative Josh Harder (CA-10) on November 20, 2019. H.R. 5190 proposes to provide assistance to for health centers to implement electronic provider consultation services. Specifically, H.R. 5190 would provide grants to health centers and rural health clinics to conduct pilot projects on the effectiveness of e-consult services and telehealth services.

Community Action Alerts & Policy Resources

The EveryLife Foundation and other patient community organizations are seeking the support of fellow patient advocacy community organizations wishing to join in offering support for existing Hill proposals that include provisions for best price/AMP exemptions. In recent months, there has been significant Hill activity to create legislative fixes to existing barriers in implementing innovative payment solutions for the emerging transformative & gene therapies. While many coalition groups have been active on these issues, they have not included strong patient community voices and thus the Hill has asked that we specifically weigh in on the need for
legislation to allow for outcomes-based agreements for innovative and gene therapy. This proposed legislative solution establishes a flexible framework that would enable biopharmaceutical companies and payers to develop customized approaches that ultimately foster patient access. To add your organization to those supporting this Hill outreach, please indicate your interest in signing the letter by emailing Steve Silvestri at the EveryLife Foundation by 12 noon on Wednesday, December 11th at ssilvestri@everylifefoundation.org.

The March of Dimes is asking organizations to sign on to a letter addressed to HHS Secretary Azar urging him to immediately act to extend the term of the Advisory Committee on Heritable Disorders in Newborns and Children until the Newborn Screening Saves Lives Act is reauthorized. To view the letter, click here. To sign complete this form by Wednesday, December 18th.

The Friends of PCORI Reauthorization is asking advocates to contact their Members of Congress in support of the Patient Centered Outcomes Research Institute (PCORI) reauthorization. PCORI supports research to help patients and providers make evidence-based healthcare decisions. To find sample letters, click here.

Kids v. Cancer is asking organizations to sign on in support of the Creating Hope Reauthorization Act. The Creating Hope Reauthorization Act will permanently reauthorize FDA priority review vouchers (PRVs) for rare pediatric diseases. The PRV is a pediatric rare disease therapy development incentive program in which companies developing products for children with cancer and other life-threatening diseases may be eligible to receive a voucher from FDA that can be applied to the review for a future product that does not meet this same criteria. If your organization would like to officially support the Creating Hope Act, please sign on here.

The National Foundation for Ectodermal Dysplasias is asking patient advocacy organizations to sign a letter in support of the Ensuring Lasting Smiles Act. To sign on, visit the website here. NFED is also asking advocates to send emails to their legislators to ask them to co-sponsor the Ensuring Lasting Smiles Act. Please visit here.

The National PKU Alliance is asking advocates to contact their Members of Congress in support of the Medical Nutrition Equity Act, H.R. 2105. H.R. 2105 would provide coverage of medically necessary foods and vitamins for digestive and inherited metabolic disorders under federal health programs and private health insurance. To contact your Representative to cosponsor H.R. 2105, click here.

National Society of Genetic Counselors is asking advocates to contact their Members of Congress in support of the Access to Genetic Counselors Act, H.R. 3235. H.R. 3235 would expand coverage of services provided by genetic counselors under the Medicare program. To contact your Representatives to cosponsor H.R. 3235, click here.

The Aidan Jack Seeger Foundation is asking organizations to sign onto a letter in support of Aidan's Law, H.R. 534, to make newborn screenings of MPS1, Pompe, ALD, and SMA available nationwide. To view and sign on to the letter, click here.
The EveryLife Foundation for Rare Diseases is circulating a sign on letter to support the **Advancing Access to Precision Medicine Act**. This legislation would ensure that many children and young adults living with an undiagnosed condition will have access to DNA sequencing clinical services beyond Whole Genome Sequencing that are currently out of reach. Please contact Steve Silvestri (ssilvestri@everylifefoundation.org) if your patient organization would like to sign.

**Community Events**

*Below are upcoming policy and advocacy events of interest to the rare disease community. To view more policy and advocacy events for this year and beyond, please visit the RDLA events calendar.*

**Informational Webinar on Rare Disease Week** will take place on December 12, 2019. The webinar will cover an overview of the events, travel stipends, and the Legislative Conference and include time for questions. Register to join on the RDLA website.

**Expanded Access Summit:** Wide Trial invites patient advocates, industry, academia and nonprofits to the Third Annual Expanded Access Summit at the National Press Club in Washington, DC on January 27-29th. This Summit is free to patients. Learn more [here](#).

**Rare Disease Week on Capitol Hill, February 25-28, 2020:** RDLA will bring hundreds of rare disease patient advocates to Washington, DC for a week of events dedicated to empowering patients, families, and friends to become legislative advocates. Advocates will have an opportunity to meet with Members of Congress and learn best practices for successful advocacy. Please find a list of the week’s events at [www.rareadvocates.org/rdw](http://www.rareadvocates.org/rdw).

Registration for the event begins on January 3, 2020 at [www.rareadvocates.org/rdw](http://www.rareadvocates.org/rdw).

On February 28th, as part of Rare Disease Week on Capitol Hill, the NIH will host Rare Disease Day at NIH. This event aims to raise awareness about rare diseases, the people they affect and NIH research collaborations to advance new treatments.

**FDA Public Workshop:** The Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration (FDA) announced a public workshop entitled "Facilitating End-to-End Development of Individualized Therapeutics” on March 3, 2020. The purpose of the public workshop is to foster development of individualized therapeutic products for the treatment of one individual or a very small number of patients, based on engineering a product aimed at the specific molecular mechanism underlying a patient’s (or small group of patients’) illness. For more information and to register, [click here](#).

**Stay Connected**
Stay up to date on breaking rare disease legislative news by following @RareAdvocates on Twitter and Facebook and rare_advocates on Instagram.
Receive this from a friend? Sign-up for our email list to make sure you don’t miss monthly newsletters and action alerts!

***This E-Blast shares action alerts, legislative, and policy news and events from the patient advocacy community. RDLA does not take positions on the issues herein but serves as a supportive clearinghouse for the rare disease community. Send us an email if you’d like your alerts and/or events included! Email svonfelden@everylifefoundation.org.